The substantial cash raise provides runway for paxalisib's breast cancer development, but the increased loss and significant share dilution (4.5B new shares in December PIPE) are concerns. Monitor upcoming clinical data and watch for insider selling given the recent Nasdaq compliance resolution and capital raise.
Price Chart
Executive Summary
Kazia Therapeutics reported a half-year loss of $12.55M (up from $10.45M) with strong cash generation of $69.46M from a $46.5M PIPE and other financings. The company advanced paxalisib into breast cancer trials with promising early data and regained Nasdaq compliance. A new ATM agreement with Leerink Partners enhances future capital flexibility.
Key Facts
- Half-year net loss of $12,552,490 (vs $10,453,811 in prior year), driven by increased R&D and G&A expenses
- Raised $69.46M in cash, including $46.5M net proceeds from a December 2025 PIPE and $21.6M from pre-funded warrant exercises
- Advanced paxalisib into breast cancer with positive data: >50% CTC reduction, 86% tumor burden reduction in expanded-access cases
- Regained Nasdaq compliance after prior non-compliance with minimum market value requirements
- Entered new $50M ATM agreement with Leerink Partners, replacing Rodman & Renshaw
Financial Impact
Cash balance increased from $4.3M to $69.5M; $46.5M net from PIPE; $21.6M from warrant exercises; $1.4M from ATM
Risk Factors
- Continued high cash burn ($9.5M in operating activities) despite large capital raise
- Significant shareholder dilution from multiple financings and warrant exercises
- Clinical trial results remain early-stage and from small patient cohorts
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-035886 |
| Document: ea0283661-6k_kazia.htm | 0001213900-26-035886 |
| Document: 0001213900-26-035886-index-headers.html | 0001213900-26-035886 |
| Document: 0001213900-26-035886-index.html | 0001213900-26-035886 |
| Document: 0001213900-26-035886.txt | 0001213900-26-035886 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 24d ago | SC 13G/A | $9.27 | awaiting T+20 | — | $8.30 (−10.46%) |
Sep 22, 2026 5w ago | 6-K | $10.92 $7.88 | ▼ −27.84% | ▼ −27.28% | $8.30 (−23.99%) |
Sep 1, 2026 7w ago | 6-K | $12.61 $9.60 | ▼ −23.91% | ▼ −23.58% | $8.30 (−34.18%) |
Aug 31, 2026 8w ago | Press Release | $12.63 $9.60 | ▲ +24.03% | ▲ +24.35% | $8.30 (+34.28%) |
Aug 31, 2026 8w ago | 6-K | $13.77 $9.75 | ▼ −29.19% | ▼ −29.01% | $8.30 (−39.72%) |
Aug 31, 2026 8w ago | 6-K | $13.77 $9.75 | ▲ +29.19% | ▲ +29.01% | $8.30 (+39.72%) |
Aug 31, 2026 8w ago | 424B5 | $13.77 $9.75 | ▲ +29.19% | ▲ +29.01% | $8.30 (+39.72%) |
Aug 28, 2026 8w ago | 6-K / 424B5 | $13.58 $9.60 | ▲ +29.31% | ▲ +29.57% | $8.30 (+38.88%) |
Aug 28, 2026 8w ago | 424B5 | $13.58 $9.60 | ▼ −29.31% | ▼ −29.57% | $8.30 (−38.88%) |
Jul 28, 2026 13w ago | 6-K | $12.69 $13.79 | ▲ +8.67% | ▲ +5.29% | $8.30 (−34.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers